295 related articles for article (PubMed ID: 11835212)
1. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
[TBL] [Abstract][Full Text] [Related]
2. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.
Webb SD; Golledge SL; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Jun; 91(6):1474-87. PubMed ID: 12115847
[TBL] [Abstract][Full Text] [Related]
3. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2003 Apr; 92(4):715-29. PubMed ID: 12661058
[TBL] [Abstract][Full Text] [Related]
4. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres.
Cleland JL; Jones AJ
Pharm Res; 1996 Oct; 13(10):1464-75. PubMed ID: 8899836
[TBL] [Abstract][Full Text] [Related]
5. Electrochemical determination of dissolution rates of lyophilized pharmaceutical formulations.
Webb SD; Koval CA; Randolph CM; Randolph TW
Anal Chem; 2001 Nov; 73(21):5296-301. PubMed ID: 11721932
[TBL] [Abstract][Full Text] [Related]
6. The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution.
Jones LS; Randolph TW; Kohnert U; Papadimitriou A; Winter G; Hagmann ML; Manning MC; Carpenter JF
J Pharm Sci; 2001 Oct; 90(10):1466-77. PubMed ID: 11745706
[TBL] [Abstract][Full Text] [Related]
7. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
8. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.
Sarciaux JM; Mansour S; Hageman MJ; Nail SL
J Pharm Sci; 1999 Dec; 88(12):1354-61. PubMed ID: 10585234
[TBL] [Abstract][Full Text] [Related]
9. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
[TBL] [Abstract][Full Text] [Related]
10. Lyophilization-induced protein denaturation in phosphate buffer systems: monomeric and tetrameric beta-galactosidase.
Pikal-Cleland KA; Carpenter JF
J Pharm Sci; 2001 Sep; 90(9):1255-68. PubMed ID: 11745778
[TBL] [Abstract][Full Text] [Related]
11. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
12. Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Nuijen B; Bouma M; Talsma H; Manada C; Jimeno JM; Lopez-Lazaro L; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2001 Sep; 27(8):767-80. PubMed ID: 11699828
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation.
Chi EY; Weickmann J; Carpenter JF; Manning MC; Randolph TW
J Pharm Sci; 2005 Feb; 94(2):256-74. PubMed ID: 15570600
[TBL] [Abstract][Full Text] [Related]
14. Development of lyophilized gemini surfactant-based gene delivery systems: influence of lyophilization on the structure, activity and stability of the lipoplexes.
Mohammed-Saeid W; Michel D; El-Aneed A; Verrall RE; Low NH; Badea I
J Pharm Pharm Sci; 2012; 15(4):548-67. PubMed ID: 23106958
[TBL] [Abstract][Full Text] [Related]
15. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ.
Osterberg T; Fatouros A; Mikaelsson M
Pharm Res; 1997 Jul; 14(7):892-8. PubMed ID: 9244146
[TBL] [Abstract][Full Text] [Related]
16. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
[TBL] [Abstract][Full Text] [Related]
17. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
[TBL] [Abstract][Full Text] [Related]
18. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at -20 degrees C of a recombinant hemoglobin.
Kerwin BA; Heller MC; Levin SH; Randolph TW
J Pharm Sci; 1998 Sep; 87(9):1062-8. PubMed ID: 9724555
[TBL] [Abstract][Full Text] [Related]
19. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
[TBL] [Abstract][Full Text] [Related]
20. Development of a lyophilized formulation of interleukin-2.
Hora MS; Rana RK; Wilcox CL; Katre NV; Hirtzer P; Wolfe SN; Thomson JW
Dev Biol Stand; 1992; 74():295-303; discussion 303-6. PubMed ID: 1592178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
